Our Chief Business Officer is speaking at this event.
Join and network with over 200 industry leaders at Discovery US: In-Person, where we will address the latest advancements in target identification, validation and HIT optimisation.
Richard Willock will be presenting in the identification & validation of novel targets, new modalities session scheduled for November 17th at 9.30am.
The 2-day programme addresses drug discovery in new modalities such as protein degradation, and case studies on the integration of screening approaches in phenotypic and genomics-based discovery, Organ-on-a-chip and 3D modelling. Learn more about the conference here.